Allergy Immunotherapy Market 2026

Allergy Immunotherapy is best assessed as a collection of allergen-specific offerings and access pathways, not as one interchangeable treatment category. ALK's commercial reporting distinguishes sublingual tablets, injections and sublingual drops, including bulk extracts sold primarily to US allergists. Germany's authorization listings also identify insect-venom immunotherapy alongside respiratory-allergen categories.

The central commercial question is whether an offering connects an authorized indication with an accessible prescribing and distribution channel. Manufacturers and licensing partners supply products and develop markets; prescribers and purchasing organizations require clarity about the particular product's status and availability. These roles should not be confused with evidence of patient uptake.

This report includes respiratory, venom and food-allergen immunotherapy commercial developments. Diagnostics and emergency anaphylaxis products are adjacent categories, not substitutes to be counted automatically as immunotherapy. The analysis prioritizes documented portfolio status, channel responsibilities and market-access conditions rather than market-size estimates.

Three dated developments show why market access should not be reduced to a single growth narrative. On February 27, 2025, FDA expanded Odactra's indication to children aged five through eleven. This enlarged the authorized patient population; it did not itself establish reimbursement, prescriber adoption or realized sales.

ALK's GenSci partnership became effective October 1, 2025. Its announcement assigned local commercial-development responsibilities and described planned investment in professional education and hospital, allergy-center and digital channels. These are partnership commitments, not proof that every channel has been implemented. On October 19, 2026, ALK said an ACARIZAX filing in China was expected in the first half of 2027: that tablet remained a prospective regulatory opportunity in the inspected announcement.

In contrast, Greer Laboratories' current Palforzia program notice states that the product has been withdrawn from the United States and is no longer available for commercial distribution. The commercial synthesis is that broader respiratory indications can coexist with a food-immunotherapy product exit. Authorization, channel investment and continuing portfolio availability must be evaluated independently.

The inspected evidence did not establish a deployed AI offering, named organizational adoption or measured commercial benefit specific to allergy immunotherapy sales, customer service or market-access work. The China partnership announcement includes planned online-pharmacy and telemedicine collaborations, but digital channels are not evidence of AI adoption.

A plausible business application is assisted comparison of public product records, local portfolio changes and distributor responsibilities. This is an analytical possibility, not an observed market outcome. Human review would remain necessary to distinguish an approval from a launch and an affiliate from a distributor—distinctions that materially change commercial interpretation.

The cumulative impact cannot responsibly be characterized as established productivity or adoption growth. A proportionate approach is a bounded information-work pilot with source traceability, correction tracking and a non-AI comparator, excluding clinical decisions and technical production guidance.

North America illustrates divergent portfolio outcomes: US respiratory-immunotherapy eligibility expanded through Odactra's pediatric approval, while Palforzia exited commercial distribution. The implication is to evaluate category breadth and continuity separately, rather than extrapolate one product's trajectory across the region.

Europe presents a channel-capacity question as well as a regulatory one. ALK reported that constrained allergy-clinic capacity and some patient movement toward tablets affected injection-product initiations in Germany and the Nordics. This is company-attributed evidence, not a region-wide causal estimate, but it supports considering prescriber capacity when assessing commercial access.

Asia-Pacific requires separation of established registrations from prospective entry. Australia's ACARIZAX sponsor record and China's future filing announcement describe different commercial stages; neither is a proxy for regional availability.

Middle East and Africa have more limited inspected evidence. Stallergenes Greer's 2024 review reported access improvements in parts of the Middle East and North Africa for tablets and sublingual solutions. It did not provide sufficient country-level detail to establish current reimbursement or distribution across either region. North African reporting must not be generalized to all Africa.

Latin America remains a specific evidence gap in this review. Brazil's official registration portal establishes where product records can be consulted, but the inspected landing page did not resolve a named immunotherapy authorization or purchasing outcome. Regional expansion conclusions therefore remain conditional on product-level commercial evidence.

ASEAN: Singapore's Health Sciences Authority describes joint assessment of pharmaceutical applications, but each participating national authority retains its final decision. No allergy-immunotherapy-specific joint assessment outcome was established. The commercial implication is to assess product eligibility and national access separately rather than assume one regional approval.

European Union: EMA's allergen-product guideline for moderate to low-sized study populations became effective January 1, 2026. This is a regulatory-framework development, not a product approval or reimbursement decision. It provides context for portfolio planning, while the national records discussed below remain necessary for access assessment.

GCC: The Gulf Health Council describes central registration and pricing-harmonization arrangements. The inspected institutional record does not identify an allergy immunotherapy approval or procurement outcome. A regional filing strategy therefore remains conditional on product-specific eligibility and documented local access.

BRICS, G7 and NATO: Research did not establish an allergy-immunotherapy-specific common authorization, purchasing program or reimbursement measure for these groupings. Their inclusion in the reporting scope does not establish a shared commercial market. For BRICS, the unresolved question is whether any relevant joint initiative changes product access; for G7, whether cooperation translates into product-specific purchasing or coverage; for NATO, whether any relevant procurement channel exists. No bloc-wide adoption conclusion is supported.

North America — United States, Canada and Mexico: The United States combines the documented Odactra pediatric expansion with Palforzia's subsequent commercial withdrawal. Canada features in ALK's reporting of pediatric house dust mite and tree-tablet launches during 2025; current province-level reimbursement was not established. Mexico's 2019 professional guideline reported commercially available extracts associated with European and American practice traditions. That historical record does not identify today's active suppliers, registrations or payer coverage.

Latin America — Brazil: Anvisa's public registration portal was inspected, but a named immunotherapy product's status was not resolved. The actionable uncertainty is which exact offering has a current lawful commercial pathway and who distributes and pays for it—not whether the country should be presumed inactive.

Europe — France, Germany, Italy and Spain: ALK's French portfolio identifies OSIRIS within the APSI category and describes direct patient delivery following receipt of a prescription, making prescription-linked distribution commercially relevant. Germany's Paul-Ehrlich-Institut lists authorized immunotherapy products but explicitly does not establish their market availability. Italy's AIFA maintains allergen-product lists and transitional-status notices; product-by-product status matters more than a general claim of market participation. Spain's AEMPS distinguishes therapeutic from diagnostic allergens and publishes a category-based regulatory calendar. Neither the Italian nor Spanish umbrella page alone establishes a particular supplier's current sales.

Europe — United Kingdom and Russia: Allergy UK's January 28, 2026 statement reported the manufacturer's worldwide Palforzia production-discontinuation decision and restrictions on new starts after April 1, while discussing continuity for existing patients. It should not be read as the same event as the US distribution withdrawal or as a complete inventory statement. Stallergenes Greer lists a Russian affiliate, establishing organizational presence, not current availability, reimbursement or sales of individual products.

Asia-Pacific — Australia, China and Japan: Australia's TGA record identifies Seqirus as ACARIZAX's sponsor; current stock and reimbursement require separate evidence. In China, ALK's October 2026 announcement places ACARIZAX at the anticipated-filing stage, distinct from existing-product partnership activity. Japan has established MITICURE and CEDARCURE offerings in ALK's reporting; that does not establish availability of every tablet in its international portfolio.

Asia-Pacific — India and South Korea: India's inspected CDSCO interface did not yield a resolved immunotherapy-specific approval record, leaving named-product authorization and distribution uncertain. South Korea's 2024 association guideline identifies house dust mite sublingual offerings and local commercial counterparties. It supplies dated channel context, not confirmation of current stock or reimbursement.

Build product-country access records before committing expansion capital. Separate authorization, active distribution, counterparty rights, reimbursement and supply continuity. Germany's authorization-list disclaimer and Palforzia's US withdrawal demonstrate why a historical approval is insufficient. An alternative is a smaller, confirmed-access portfolio; the trade-off is narrower coverage but less exposure to unsupported launch assumptions. A documented distribution or payer decision should trigger reassessment.

Match investment to the local channel rather than favoring a format globally. France's prescription-linked APSI channel and the planned GenSci market-building activities illustrate different commercial models. Direct investment is more defensible where the company has documented rights and channel access; licensing may be preferable where a partner supplies those capabilities. Economics should be tested against public counterparty responsibilities and actual access milestones, not announced ambition alone.

Stage prospective-market spending. For China, distinguish existing-product commercial activity from ACARIZAX's anticipated filing. Preserve an option to expand after regulatory and distribution milestones rather than treating the announced timetable as committed revenue. In ASEAN, retain country-level decision gates despite joint assessment arrangements.

Treat AI as a measured information-work pilot. Compare it with conventional workflow improvement using document-review time, correction rates and auditability. Do not justify substantial investment through unestablished immunotherapy adoption or sales benefits.

This qualitative review uses public records inspected for a November 5, 2026 reporting cutoff. Research compared regulator product records, official portfolio and affiliate pages, licensing announcements, company annual reports and selected professional-association records. Native-language French, Italian, Spanish and Brazilian pages were inspected where relevant. Association publications were used only for separable commercial-category or historical availability statements, not treatment instructions.

Claims were separated into authorization, announced development, commercial distribution, organizational presence and reimbursement. Germany's regulator explicitly distinguishes authorization from availability. The later US Palforzia withdrawal notice was not displaced by older portfolio descriptions; UK supply-continuity reporting was retained within its different geographic scope.

Coverage is uneven. Company reports describe their own businesses, not the whole market; older Mexican and Korean records cannot establish current availability. Brazilian and Indian registry interfaces did not resolve named-product status. No interviews, surveys, patient-level research, market sizing, statistical forecasts or completed commercial diligence were performed. AI benefits and several group-level access questions remain unestablished. Scientific methods, manufacturing instructions and treatment guidance were outside this commercial assignment.

The established record supports a selective outlook rather than a uniform expansion claim. Pediatric respiratory-immunotherapy authorization has broadened in the United States, while Palforzia's US withdrawal shows that a prior approval does not ensure continuing commercial participation. These events make portfolio durability and channel access central to commercial assessment.

The most useful observable milestones are product-specific: China's anticipated ACARIZAX filing in the first half of 2027, subsequent regulatory decisions, documented distribution arrangements and payer-access outcomes. The Chinese timetable remains an announced expectation, not a forecast of approval or success.

The synthesis is that companies with clearly documented product status, counterparty responsibilities and access pathways are better positioned to make disciplined investment choices. Unresolved availability, reimbursement and AI-adoption evidence should remain explicit decision conditions rather than be converted into assumed demand or commercial forecasts.